Home Metabolism IDO/TDO

IDO/TDO

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S8037 Necrostatin-1 (Nec-1) Necrostatin-1 (Nec-1) is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.
Cell Res, 2025, 10.1038/s41422-025-01167-8
Signal Transduct Target Ther, 2025, 10(1):341
Cancer Discov, 2025, 10.1158/2159-8290.CD-24-1317
Verified customer review of Necrostatin-1 (Nec-1)
S7910 Epacadostat (INCB024360) Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with an IC50 of 10 nM, and it displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO).
Immunity, 2025, 58(1):247-262.e9
Mol Cell Proteomics, 2025, 24(9):101048
Commun Chem, 2025, 8(1):277
Verified customer review of Epacadostat (INCB024360)
S7111 IDO-IN-2 IDO-IN-2 (RG 6078, NLG-919 analogue, GDC-0919 analogue) is a a potent IDO1 inhibitor with IC50 of 38 nM.
European Respiratory Journal, May 13, 2021, 2000443
Cell Death & Disease, July 19, 2019, 557
Acta Pharm Sin B, 2022, 12(6):2695-2709
Verified customer review of IDO-IN-2
S7756 Indoximod Indoximod, a methylated tryptophan, acts as an IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, and reverses IDO-mediated immune suppression. Phase 2.This product has poor solubility, animal experiments are available, cell experiments please choose carefully!
eLife, October 5, 2020, e56749
European Respiratory Journal, May 13, 2021, 2000443
Front Immunol, 2024, 15:1331480
S8957 Navoximod Navoximod (GDC-0919, NLG-919) is a potent inhibitor of IDO (indoleamine-(2,3)-dioxygenase) pathway with Ki of 7 nM and EC50 of 75 nM.
Frontiers in Immunology, November 4, 2025, 16:1680896
ACS Nano, December 22, 2020, 17100-17113
J Colloid Interface Sci, 2025, 686:1019-1032
S8657 PF-06840003 PF-06840003 (EOS200271) is a highly selective orally bioavailable IDO-1 inhibitor. Although this compound has moderate hIDO1 enzyme inhibition (IC50 0.41 μM), it is a highly efficient compound (LE 0.53, LipE 5.1), driven by its tight packing within the enzyme, as well as the high density of hydrogen bonds it forms with hIDO-1 despite its small size.
Cells, May 14, 2020, 1222
Frontiers in Immunology, 2023, 1100041
Front Immunol, 2023, 14:1100041
S8629 Linrodostat (BMS-986205) Linrodostat (BMS-986205, ONO-7701) is an irreversible inhibitor of IDO1 with an IC50 of 1.7 nM. It inhibits kynurenine production with IC50 values of 1.7, 1.1 and > 2000 in human HeLa, HEK293 expressing human IDO-1 and tryptophan-2, 3-dioxygenase cell-based assays.
Front Chem, 2022, 10:998013
Front Oncol, 2021, 11:679517
Eur Respir J, 2020, 2000443
S8368 LM10 LM10 is a selective tryptophan 2,3-dioxygenase (TDO) inhibitor with IC50 values of 0.62 and 2 μM for human and mouse TDO, respectively.
Brain, Behavior, and Immunity, 2023, 173-186
Sci Adv, 2023, 9(5):eadd6995
Mol Med Rep, 2021, 23(6)445
S8997 680C91 680C91 is a potent and selective inhibitor of TDO with Ki of 51 nM.
Cancer Research Communications, March 18, 2024, 822-833
Journal of Proteome Research, April 5, 2024, 1341-1350
Cancer Res Commun, 2024, 4(3):822-833
S7587 Epacadostat (INCB024360) analogue Epacadostat (INCB024360) analogue (INCB14943) is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM.
Biomed Pharmacother, 2024, 179:117412
Front Immunol, 2022, 13:966514
OncoImmunology, 2017, e1361594